These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37510722)

  • 1. Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?
    Strzelczyk J; Wójcik-Giertuga M; Strzelczyk JK; Seńkowska AP; Biernacki K; Kos-Kudła B
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.
    Malyszko J; Malyszko JS; Wolczynski S; Mysliwiec M
    Transplant Proc; 2003 Sep; 35(6):2227-9. PubMed ID: 14529897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60.
    Kim JG; Shin CS; Choi YM; Moon SY; Kim SY; Lee JY
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):301-7. PubMed ID: 10469009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between age-related biochemical markers of bone turnover and OPG, TGF-β1 and TGF-β2 in native Chinese women.
    Chen C; Liang MK; Zhang H; Peng YQ; Wu XP; Wu XY; Liao EY
    Endocr Res; 2014; 39(3):105-14. PubMed ID: 24152296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
    Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy.
    Styczynska H; Lis K; Sobanska I; Pater A; Pollak J; Mankowska A
    EJIFCC; 2009 Jan; 19(4):193-202. PubMed ID: 27683317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors.
    van Adrichem RC; Hofland LJ; Feelders RA; De Martino MC; van Koetsveld PM; van Eijck CH; de Krijger RR; Sprij-Mooij DM; Janssen JA; de Herder WW
    Endocr Connect; 2013; 2(4):172-7. PubMed ID: 24042314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D; Neacşu E; Marinescu M; Popa O
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological Features of Neuroendocrine Tumors in Gastroenteropancreatic Tract: A Single Center Study.
    Rafique Z; Qasim A; Zafar A; Ali S; Chughtai AS; Atiq A
    Cureus; 2022 Jul; 14(7):e27384. PubMed ID: 36046310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
    Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.